Increased BTB-Kelch type substrate adaptor protein immunoreactivity associates with advanced stage and poor differentiation in renal cell carcinoma

Oncology Reports

Volumn 21, Issue 6, 2009, Pages 1519-1523

  Ronkainen, Hanna ^a   Vaarala, Markku H ^a   Kauppila, Saila ^a   Soini, Ylermi ^b   Paavonen, Timo K ^c   Rask, Jenni ^a   Hirvikoski, Pasi ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

BTB Kelch type substrate adaptor protein; Oxidative system; Prognosis; Renal cell carcinoma; Thioredoxin

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; NFE2 PROTEIN, HUMAN; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR NF E2 P45 SUBUNIT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; PRIORITY JOURNAL; PROGNOSIS; CHEMISTRY; CYTOPLASM; KAPLAN MEIER METHOD; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIERS ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEPHRECTOMY; NF-E2 TRANSCRIPTION FACTOR, P45 SUBUNIT; PROPORTIONAL HAZARDS MODELS; THIOREDOXINS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 67649959800     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000383     Document Type: Article

References (30)

1. Pantuck AJ, Zisman A and Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 166: 1611-1623, 2001.
2. Bui MH, Zisman A, Pantuck AJ, et al: Prognostic factors and molecular markers for renal cell carcinoma. Expert Rev Anticancer Ther 1: 565-575, 2001.
3. Cheville JC, Lohse CM, Zincke H, et al: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624, 2003.
4. Lang H, Lindner V, Letourneux H, et al: Prognostic value of microscopic venous invasion in renal cell carcinoma: Long-term follow-up. Eur Urol 46: 331-335, 2004.
5. George S and Bukowski RM: Biomarkers in clear cell renal cell carcinoma. Expert Rev Anticancer Ther 7: 1737-1747, 2007.
6. Mates JM, Segura JA, Alonso FJ, et al: Intracellular redox status and oxidative stress: Implications for cell proliferation, apoptosis, and carcinogenesis. Arch Toxicol 82: 273-299, 2008.
7. Fridovich I: Oxygen toxicity: A radical explanation. J Exp Biol 201: 1203-1209, 1998.
8. Oberley TD: Oxidative damage and cancer. Am J Pathol 160: 403-408, 2002.
9. Zelko IN, Mariani TJ and Folz RJ: Superoxide dismutase multigene family: A comparison of the CuZn-SOD (SOD1), mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33: 337-349, 2002.
10. Itoh K, Wakabayashi N, Katoh Y, et al: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13: 76-86, 1999.
11. Liu H, Colavitti R, Rovira II, et al: Redox-dependent transcriptional regulation. Circ Res 97: 967-974, 2005.
12. Arner ES and Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
13. Powis G and Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41: 261-295, 2001.
14. Powis G, Mustacich D and Coon A: The role of the redox protein thioredoxin in cell growth and cancer. Free Radic Biol Med 29: 312-322, 2000.
15. Soini Y, Kallio JP, Hirvikoski P, et al: Antioxidant enzymes in renal cell carcinoma. Histol Histopathol 21: 157-165, 2006.
16. UICC (2002): TNM Classification of Malignant Tumours. 6th edition. Wiley & Sons, New York, 2002.
17. IARC (2004): Tumours of the Urinary System and Male Genital Organs. IARC Press, Lyon, 2004.
18. Ohta T, Iijima K, Miyamoto M, et al: Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68: 1303-1309, 2008.
19. Singh A, Misra V, Thimmulappa RK, et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 3: e420, 2006.
20. Nioi P and Nguyen T: A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362: 816-821, 2007.
21. Stacy DR, Ely K, Massion PP, et al: Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 28: 813-818, 2006.
22. Yamamoto T, Suzuki T, Kobayashi A, et al: Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity. Mol Cell Biol 28: 2758-2770, 2008.
23. McMahon M, Itoh K, Yamamoto M, et al: Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem 278: 21592-21600, 2003.
24. Apopa PL, He X and Ma Q: Phosphorylation of Nrf2 in the transcription activation domain by casein kinase 2 (CK2) is critical for the nuclear translocation and transcription activation function of Nrf2 in IMR-32 neuroblastoma cells. J Biochem Mol Toxicol 22: 63-76, 2008.
25. Powis G, Kirkpatrick DL, Angulo M, et al: Thioredoxin redox control of cell growth and death and the effects of inhibitors. Chem Biol Interact 111-112: 23-34, 1998.
26. Sasada T, Nakamura H, Ueda S, et al: Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic Biol Med 27: 504-514, 1999.
27. Grogan TM, Fenoglio-Prieser C, Zeheb R, et al: Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31: 475-481, 2000.
28. Rubartelli A, Bonifaci N and Sitia R: High rates of thioredoxin secretion correlate with growth arrest in hepatoma cells. Cancer Res 55: 675-680, 1995.
29. Soini Y, Kahlos K, Napankangas U, et al: Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.
30. Haapasalo H, Kylaniemi M, Paunul N, et al: Expression of antioxidant enzymes in astrocytic brain tumors. Brain Pathol 13: 155-164, 2003.